3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
16
Carcinoma, Intraductal, Noninfiltrating
5
Breast Carcinoma In Situ
4
Neoplasms
2
Infertility
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Polycystic Ovary Syndrome
1
Pancreatic Cyst
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms, Male
1
Anovulation
1
Interventions
Fulvestrant
2
tivozanib
1
ribociclib
1
palbociclib
1
niraparib
1
lorlatinib
1
exemestane
1
encorafenib
1
cemiplimab
1
binimetinib
1
abemaciclib
1
Tamoxifen
1
STX-478
1
Metformin
1
Letrozole
1
Imlunestrant
1
Cetuximab
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Tamoxifen
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled